Evidence map›Paper›PMID 33398393›Full record

ArticleEuropean journal of clinical pharmacology2021

CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.

Janaína B F Everton, Fernando J B Patrício, Manuel S Faria, Teresa C A Ferreira, Elen A Romao, Gyl E B Silva, Marcelo Magalhães

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Janaína B F EvertonLaboratory of Genomic and Histocompatibility Studies, University Hospital of the Federal University of Maranhão, São Luís, Brazil.
Fernando J B PatrícioLaboratory of Genomic and Histocompatibility Studies, University Hospital of the Federal University of Maranhão, São Luís, Brazil.
Manuel S FariaPostgraduate Program in Adult Health (PPGSAD), Federal University of Maranhão, São Luís, Brazil.
Teresa C A FerreiraKidney Transplant Unit, University Hospital of the Federal University of Maranhão, São Luís, Brazil.
Elen A RomaoDepartment of Internal Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Gyl E B SilvaPostgraduate Program in Adult Health (PPGSAD), Federal University of Maranhão, São Luís, Brazil.
Marcelo MagalhãesLaboratory of Genomic and Histocompatibility Studies, University Hospital of the Federal University of Maranhão, São Luís, Brazil. magalhaes_ms@yahoo.com.br.ORCID http://orcid.org/0000-0002-0464-4343
Universidade Federal do Maranhão · BRHospital Universitário da Universidade Federal do Maranhão · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenetic polymorphisms have been associated with variation in the metabolism of tacrolimus (TAC) in kidney transplant patients. This study is aimed at assessing the impact of allelic variants of CYP3A5 and PPARA genes on the pharmacokinetics (PK) of TAC in Brazilian kidney transplant recipients in the first-year post-transplant.

methodsA total of 127 patients were included for genetic evaluation. Genomic DNA was isolated from peripheral blood and real-time PCR was used to analyze the main polymorphisms described for the genes CYP3A5 (rs776746; C > G) and PPARA (rs4823613; A > G and rs4253728; G > A).

resultsCYP3A5 expressors showed a lower Co/dose ratio than non-expressors, with the median values of this parameter <1.01 ng/mL/mg in the first group at all evaluated times. Additionally, PPARA variant homozygotes had a lower Co/D ratio than wild allele carriers in the 12-month post-transplant period, with a median value of 0.65 ng/mL/mg. In the CYP3A5 expressers, the presence of the variant homozygous genotype PPARA was associated with a lower value of Co/D compared with the other genotypic groups at month 12.

conclusionIn the population under study, polymorphisms on CYP3A5 and PPARA were identified as determining and independent factors associated with the reduction of Co/D of TAC. Thus, the genotyping of these genetic variants may be a useful tool for the individualized prescription of TAC in kidney transplant patients.

Indexed as

Transplant RecipientsAdultAllelesBrazilCytochrome P-450 CYP3AFemaleHumansImmunosuppressive AgentsKidney TransplantationMaleMiddle AgedPolymorphism, Single NucleotidePPAR alphaTacrolimusCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsPPAR alphaPPARA protein, humanTacrolimusCo/D ratioCYP3A5Kidney transplantationPharmacokineticsPPARATacrolimus

Identifiers

PMID33398393
OpenAlexW3119385187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.